TherapeuticsMD, Inc. 8-K


Exhibit 99.1




TherapeuticsMD Announces Third Quarter 2019 Financial Results


- 3Q19 Net Revenue (Product and License) Increased to $23.7 Million -

- 3Q19 Product Net Revenue Increased 34% to $8.2 Million Compared to 2Q19-

- The Company Reaffirms 4Q19 Financial Guidance -

- Conference Call Scheduled for 4:30 p.m. ET Today -


BOCA RATON, Fla. November 6, 2019 – TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today reported financial results for the third quarter ended September 30, 2019 and provided a business update.


“We are very pleased with our results for the quarter, which are in-line with our financial guidance, and reaffirm our fourth quarter 2019 financial guidance,” said Robert G. Finizio, Chief Executive Officer of TherapeuticsMD. “This reiterates our confidence that we will be able to access an additional $50 million in capital from our term loan facility when fourth quarter 2019 results are announced. Additionally, we recently completed an equity raise that netted the company approximately $77 million and improved our liquidity. We believe we now have the resources and momentum to continue to fully execute our plans into 2020 and beyond.”


Third Quarter and Recent Developments

IMVEXXY® (estradiol vaginal inserts) third quarter 2019 product net revenue increased by 53% to approximately $4.8 million and prescriptions dispensed and paid for by patients increased 26% to approximately 134,000 as compared to the second quarter of 2019. Strong refill rates continued with patients adhering to therapy at an average rate of four fills per year through September 2019.
IMVEXXY has market access for the majority of lives under commercial plans with approximately 68% unrestricted commercial access. IMVEXXY is now covered by eight of the ten top commercial payers of vulvar and vaginal atrophy (VVA) products. A ninth top-ten commercial payer will adjudicate beginning in January 2020. Two of the top six Medicare Part D payers of VVA products cover IMVEXXY and additional Medicare coverage decisions are expected by the end of 2019.
BIJUVA® (estradiol and progesterone) capsules third quarter 2019 product net revenue and prescriptions increased two-fold to approximately $0.5 million and approximately 15,800 prescriptions dispensed and paid for by patients during the third quarter as compared to the second quarter of 2019.
BIJUVA currently has approximately 55% unrestricted commercial access and is covered by six of the top ten commercial payers.
ANNOVERA(segesterone acetate and ethinyl estradiol vaginal system) generated third quarter product net revenue of approximately $0.4 million. The company is in the “test and learn” market introduction phase of launch for ANNOVERA, the first and only long-lasting, patient-controlled, procedure-free, reversible prescription contraceptive option for women.
ANNOVERA has already achieved approximately 62% unrestricted commercial access and is covered by six of the top ten commercial payers by commercial payer lives.
On October 29, 2019, the company received net proceeds of approximately $77.0 million from an underwritten public offering of its common stock to support commercialization efforts for its three FDA-approved products and to maximize ANNOVERA’s consumer-focused commercialization strategy.





Summary of Third Quarter 2019 Financial Results

Total net revenue increased to approximately $23.7 million, for the third quarter of 2019 compared with net revenue of approximately $3.5 million for the prior year’s quarter. During the third quarter of 2019, the company recognized license revenue of approximately $15.5 million from the upfront fee, a non-refundable payment, under the company’s license agreement with Theramex, which is included in total revenue for the quarter.


Product net revenue increased to approximately $8.2 million, for the three months ended September 30, 2019 compared with approximately $3.5 million for the three months ended September 30, 2018. Product net revenue increased primarily due to increases in sales of approximately $4.5 million of IMVEXXY in the current period, partially offset by a decrease in prenatal vitamin sales of approximately $0.7 million. Product net revenue for the three months ended September 2019 also included sales of BIJUVA of approximately $0.5 million and sales of ANNOVERA of approximately $0.4 million. The revenue decrease related to our prenatal vitamins was primarily affected by a lower number of units sold as compared to the prior year period, partially offset by increased revenue per unit. The company launched IMVEXXY in the third quarter of 2018, BIJUVA in the second quarter of 2019, and ANNOVERA in the third quarter of 2019.


The following table provides information about disaggregated revenue by product mix for the three months ended September 30, 2019 and 2018:


   Three Months
September 30,
   2019  2018
Prenatal vitamins  $2,550,330   $3,261,459 
IMVEXXY   4,772,354    212,076 
BIJUVA   490,705    —   
ANNOVERA   399,952    —   
License revenue   15,506,400    —   
     Net revenue  $23,719,741   $3,473,535 


Net revenue for IMVEXXY and BIJUVA has been greatly affected by the company’s co-pay assistance programs introduced to provide products at a reasonable cost regardless of insurance coverage. We expect our product revenues to improve as commercial and Medicare payer coverage increases, and plans complete the process needed to adjudicate IMVEXXY, BIJUVA and ANNOVERA prescriptions at pharmacies.


Research and development (R&D) expenses for the third quarter of 2019 decreased to approximately $4.1 million, compared with approximately $6.7 million for the prior year’s quarter. R&D costs decreased primarily as a result of transferring certain costs and activities from R&D expenses to operations as they begin to support commercial and launch efforts after the FDA approval of IMVEXXY and BIJUVA. R&D expenses include costs related to manufacturing validation as well as early development trials and employment costs of personnel involved in R&D activities.





Sales, general and administrative (SG&A) expenses increased for the third quarter of 2019 to approximately $45.1 million, compared with approximately $30.4 million for the prior year’s quarter. The increase of SG&A expenses for third quarter 2019 was primarily a result of increased expenses associated with sales and marketing efforts and personnel costs to support the launch and commercialization of IMVEXXY, BIJUVA, and ANNOVERA including outsourced sales personnel and their related expenses, physician education, advertising, and travel expenses related to product commercialization. The company expects sales and marketing expenses to continue to increase as it continues the launch of BIJUVA and ANNOVERA and continues to support its growing business and commercialization of its products.


For the third quarter of 2019, net loss decreased to approximately $32.0 million, or $0.13 per basic and diluted share, compared with approximately $35.6 million, or $0.16 per basic and diluted share, for the third quarter of 2018.


Balance Sheet

As of September 30, 2019, the company’s cash on hand totaled approximately $155.3 million, compared with approximately $161.6 million at December 31, 2018. On October 29, 2019, the company received net proceeds of approximately $77.0 million from an underwritten public offering of its common stock.


Total outstanding debt, net of issuance costs, was approximately $194.4 million as of September 30, 2019.


Financial Guidance

The company reaffirms its previously announced fourth quarter 2019 financial guidance outlined below:


FDA-approved product net revenue is expected to be in a range of $11 million to $13 million;
Prescription prenatal vitamin net revenue is expected to be in a range of $1.75 million to $2.25 million; and
Total product net revenue is expected to be in a range of $12.75 million to $15.25 million.


Conference Call and Webcast Details

TherapeuticsMD will host a conference call and audio webcast today at 4:30 p.m. ET to discuss these financial results and provide a business update.


Date:   Wednesday, November 6, 2019
Time:   4:30 p.m. ET
Telephone Access (US):   866-665-9531
Telephone Access (International):   724-987-6977
Access Code for All Callers:   7045719


A live webcast and audio archive for the event may be accessed on the home page or from the “Investors & Media” section of the TherapeuticsMD website at Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast. A replay of the webcast will be archived on the website for at least 30 days. In addition, a digital recording of the conference call will be available for replay beginning two hours after the call's completion and for at least 30 days with the dial-in 855-859-2056 or international 404-537-3406 and Conference ID: 7045719.





Please see the Full Prescribing Information, including indication and Boxed WARNING, for each TherapeuticsMD product as follows:


IMVEXXY (estradiol vaginal inserts) at
BIJUVA (estradiol and progesterone) capsules at
ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system) at


About TherapeuticsMD, Inc.

TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. Our products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. The company is committed to advancing the health of women and championing awareness of their healthcare issues. To learn more about TherapeuticsMD, please visit or follow us on Twitter: @TherapeuticsMD and on Facebook: TherapeuticsMD.


Forward-Looking Statements

This press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company’s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in the company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: the company’s ability to maintain or increase sales of its products; the company’s ability to develop and commercialize IMVEXXY®, ANNOVERA, BIJUVA® and its hormone therapy drug candidates and obtain additional financing necessary therefor; whether the company will be able to comply with the covenants and conditions under its term loan facility, including the conditions to draw additional tranches thereunder; the potential of adverse side effects or other safety risks that could adversely affect the commercialization of the company’s current or future approved products or preclude the approval of the company’s future drug candidates; the length, cost and uncertain results of future clinical trials; the company’s reliance on third parties to conduct its manufacturing, research and development and clinical trials; the ability of the company’s licensees to commercialize and distribute the company’s products; the availability of reimbursement from government authorities and health insurance companies for the company’s products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of the company’s common stock and the concentration of power in its stock ownership. PDF copies of the company’s historical press releases and financial tables can be viewed and downloaded at its website:


# # #


Investor Contact

Nichol Ochsner

Vice President, Investor Relations

561-961-1900, ext. 2088








   September 30, 2019  December 31, 2018
Current Assets:          
Cash  $155,330,050   $161,613,077 
Accounts receivable, net of allowance for doubtful accounts of $691,699 and $596,602, respectively   15,323,614    11,063,821 
Inventory   10,532,844    3,267,670 
Other current assets   10,578,260    10,834,693 
     Total current assets   191,764,768    186,779,261 
Fixed assets, net   2,338,346    472,683 
Other Assets:          
License rights, net   39,984,002    20,000,000 
Intangible assets, net   4,942,151    4,092,679 
Right-of-use asset   10,459,635    —   
Other assets   473,009    639,301 
     Total other assets   55,858,797    24,731,980 
       Total assets  $249,961,911   $211,983,924 
Current Liabilities:          
Accounts payable  $24,133,506   $22,743,841 
Other current liabilities   43,196,032    18,334,948 
     Total current liabilities   67,329,538    41,078,789 
Long-Term Liabilities:          
Long-term debt   194,361,169    73,381,014 
Operating lease liability   9,500,133    —   
     Total liabilities   271,190,840    114,459,803 
Commitments and Contingencies          
Stockholders' Equity:          
Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding   —      —   
Common stock - par value $0.001; 350,000,000 shares authorized: 241,277,076 and 240,462,439 issued and outstanding, respectively   241,277    240,463 
Additional paid-in capital   624,515,559    616,559,938 
Accumulated deficit   (645,985,765)   (519,276,280)
     Total stockholders' (deficit) equity   (21,228,929)   97,524,121 
       Total liabilities and stockholders' equity  $249,961,911   $211,983,924 











   Three Months Ended  Nine Months Ended
   September 30,  September 30,
   2019  2018  2019  2018
Product revenue, net  $8,213,341   $3,473,535   $18,238,857   $11,009,937 
License revenue   15,506,400    —      15,506,400    —   
    Total revenue, net   23,719,741    3,473,535    33,745,257    11,009,937 
Cost of goods sold   1,444,308    699,118    3,455,995    1,786,902 
Gross profit   22,275,433    2,774,417    30,289,262    9,223,035 
Operating expenses:                    
Sales, general, and administrative   45,126,986    30,354,072    121,378,519    80,578,079 
Research and development   4,077,738    6,708,271    15,359,988    20,545,948 
Depreciation and amortization   141,959    73,321    363,956    198,545 
    Total operating expenses   49,346,683    37,135,664    137,102,463    101,322,572 
Operating loss   (27,071,250)   (34,361,247)   (106,813,201)   (92,099,537)
Other expense                    
Loss on extinguishment of debt   —      —      (10,057,632)   —   
Miscellaneous income   703,662    809,022    1,878,980    1,457,817 
Interest expense   (5,599,005)   (2,053,077)   (11,717,632)   (2,584,459)
    Total other expense   (4,895,343)   (1,244,055)   (19,896,284)   (1,126,642)
Loss before income taxes   (31,966,593)   (35,605,302)   (126,709,485)   (93,226,179)
Provision for income taxes   —      —      —      —   
Net loss  $(31,966,593)  $(35,605,302)  $(126,709,485)  $(93,226,179)
Loss per share, basic and diluted:                    
Net loss per share, basic and diluted  $(0.13)  $(0.16)  $(0.53)  $(0.42)
Weighted average number of common shares outstanding, basic and diluted   241,261,299    228,107,240    241,163,994    220,466,673 










   Nine Months Ended
   September 30,
   2019  2018
 Net loss  $(126,709,485)  $(93,226,179)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation of fixed assets   223,750    121,423 
Amortization of intangible assets   140,206    77,123 
Write off of patent and trademark cost   78,864    —   
Non-cash operating lease expense   711,836    —   
Provision for doubtful accounts   95,097    231,475 
Loss on extinguishment of debt   10,057,632    —   
Share-based compensation   7,859,357    6,388,635 
Amortization of intellectual property license fee   15,998    —   
Amortization of deferred financing fees   582,829    149,909 
Changes in operating assets and liabilities:          
Accounts receivable   (4,354,890)   (8,705,325)
Inventory   (7,265,174)   (892,863)
Other current assets   (1,128,515)   1,233,482 
Accounts payable   1,389,665    7,284,493 
Accrued expenses and other liabilities   3,402,511    8,670,986 
Net cash used in operating activities   (114,900,319)   (78,666,841)
 Payment for intellectual property license   —      (20,000,000)
 Patent costs   (1,068,542)   (748,906)
 Purchase of fixed assets   (2,089,413)   (66,295)
 Payment of security deposit   (20,420)   (11,485)
Net cash used in investing activities   (3,178,375)   (20,826,686)
 Proceeds from Financing Agreement   200,000,000    —   
 Proceeds from exercise of options and warrants   108,656    1,236,313 
 Proceeds from sale of common stock, net of costs   —      89,907,797 
 Proceeds from Credit Agreement   —      75,000,000 
 Payment of deferred financing fees   (6,652,270)   (3,786,918)
 Repayment of Credit Agreement   (81,660,719)   —   
Net cash provided by financing activities   111,795,667    162,357,192 
(Decrease) increase in cash   (6,283,027)   62,863,665 
Cash, beginning of period   161,613,077    127,135,628 
Cash, end of period  $155,330,050   $189,999,293 
Supplemental disclosure of cash flow information          
Interest paid  $12,446,792   $1,759,316 
Non-cash investing activity          
Amount accrued for intellectual property license  $20,000,000   $—   



The following information was filed by Therapeuticsmd, Inc. (TXMD) on Wednesday, November 6, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Therapeuticsmd, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Therapeuticsmd, Inc..


Never Miss A New SEC Filing Again

Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.


We Highlighted This SEC Filing For You

SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.


Widen Your SEC Filing Reading Experience

Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view


Uncover Actionable Information Inside SEC Filings

SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q


Adobe PDF, Microsoft Word and Excel Downloads

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis


FREE Financial Statements

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator

Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019) Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not


Financial Stability Report

Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019) Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity


Get a Better Picture of a Company's Performance

Financial Ratios
Available Financial Ratios Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years


Log in with your credentials


Forgot your details?

Create Account